Sarepta interest in ANP increases.

Sarepta Therapeutics, Inc. shares closed up 20.10% on Thursday with nearly 20 million shares traded compared to an average volume of roughly 1.4 million. The biotech company announced its second quarter financial results after the bell on Wednesday. Revenue for the period was $35 million, which came in higher than the $22.5 million that analysts had expected. Earnings was a loss of 46 cents per share which was also narrower than the 91 cents per share loss that analysts had called for. The company noted that strong revenue was mainly because of the company's muscular dystrophy drug, Exondys 51. A SunTrust analyst wrote in a note, "We believe Sarepta is on track to become a [Duchenne Muscular Dystrophy]-focused powerhouse." Over the last twelve months, shares of Sarepta are up over 71%."

-----------------------
IF Sarepta want to be a Duchenne Muscular Dystrophy POWER HOUSE..
THey will have to be very interested if the Royal Children's Hospital gives ANP the Green Light to conduct Trials in DMD ..
REmember Sarepta has a MC of over $2 billion.
And at present can only treat 13% of DMD..
ANP has gathered top Scientists in DMD to start trials within the next 10 days...IMO
ANP is hoping to treat 87% of DMD sufferers.